Laman UtamaFTRE • NASDAQ
add
Fortrea Holdings Inc
Tutup sebelumnya
$6.33
Julat hari
$5.92 - $6.28
Julat tahun
$4.77 - $37.84
Permodalan pasaran
564.07J USD
Bilangan Purata
2.75J
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD) | Dis 2024info | Perubahan T/T |
---|---|---|
Hasil | 697.00J | -1.79% |
Perbelanjaan pengendalian | 168.90J | 13.43% |
Pendapatan bersih | -61.20J | -12.29% |
Margin untung bersih | -8.78 | -14.32% |
Pendapatan bagi setiap syer | 0.18 | -5.26% |
EBITDA | -7.20J | -241.18% |
Kadar cukai berkesan | 1.34% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(USD) | Dis 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 118.50J | 9.12% |
Jumlah aset | 3.58B | -17.39% |
Jumlah liabiliti | 2.22B | -15.34% |
Jumlah ekuiti | 1.36B | — |
Syer tertunggak | 90.20J | — |
Harga kepada buku | 0.42 | — |
Pulangan pada aset | -1.93% | — |
Pulangan pada modal | -2.65% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(USD) | Dis 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -61.20J | -12.29% |
Tunai daripada operasi | 17.10J | -7.07% |
Tunai daripada pelaburan | 3.50J | 138.89% |
Tunai daripada pembiayaan | -1.10J | 85.71% |
Perubahan bersih dalam tunai | 13.20J | 175.00% |
Aliran tunai bebas | 90.21J | 1,006.90% |
Perihal
Fortrea Holdings Inc. is a contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates. Wikipedia
Diasaskan
Apr 1996
Tapak web
Pekerja
15,810